Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

AIDS

Volumn 28, Issue 15, 2014, Pages 2269-2279

  Castagna, Antonella ^a   Spagnuolo, V ^a   Galli, Laura ^a   Vinci, C ^a   Nozza, Silvia ^a   Carini, E ^a   Monforte, Antonella D'Arminio ^b   Montella, Francesco ^c   Antinori, A ^d   Di Biagio, Antonio ^e   Rusconi, Stefano ^f   Lazzarin, A ^a   Viscoli, C ^e   Parisini, A ^e   Prinapori, R ^e   Mazzotta, F ^g   Lo Caputo, S ^g   Di Pietro, M ^g   D'Arminio Monforte, A ^h   Tincati, C ^h   Bini, T ^h   Merlini, E ^h   Puoti, M ⁱ   Moioli, M ⁱ   Montella, M ^j   Di Sora, F ^j   Ammassari, A ^d   Ottou, S ^d   Cauda, R ^k   Di Giambenedetto, S ^k   Galli, Massimo ^f   Franzetti, M ^f   Rizzardini, G ^f   Capetti, A ^f   Cossarini, F ^a   Gianotti, N ^a   Mussini, C ^l   Guaraldi, G ^l   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^h SAN PAOLO HOSPITAL   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

Atazanavir ritonavir; HIV; Nucleos(t)ide reverse transcriptase inhibitors toxicity; Protease inhibitor monotherapy; Simplification; Virological suppression

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALKALINE PHOSPHATASE; ATAZANAVIR PLUS RITONAVIR; CREATININE; EMTRICITABINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; RITONAVIR;

ACUTE HEPATITIS; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTHRITIS; ARTICLE; CHOLECYSTITIS; CHRONOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEMATURIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTENTION TO TREAT ANALYSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; NEPHROLITHIASIS; OPEN STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS MUTATION; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84918843297     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000407     Document Type: Article

References (45)

1. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
2. Landovitz RL, Ribaudo HJ, Ofotokun I, Wang H, Baugh BP, Randi Y, et al. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC/tenofovir: ACTG 5257 [Abstract 85]. CROI Conference on Retroviruses and Opportunistic Infections 2014; 3-6 March 2014; Boston, MA.
3. Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, et al. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother 2013; 68:200-205.
4. D'Arminio Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS 2013; 27:407-415.
5. The Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002 - 2009. AIDS 2013; 27:803-813.
6. Baril J, Conway B, Giguere P, Ferko N, Hollmann S, Angel J. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction. HIV Med 2014; 15:301-310.
7. Colasanti J, Marconi VC, Babafemi T. Antiretroviral reduction: is it time to rethink the untinkable? AIDS 2014; 28:943-947.
8. Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir R lamivudine in HIVinfectedpatients on stable treatment with twonucleos(t)ide reverse transcriptase inhibitors R atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 2013; 68:1364-1372.
9. Perez-Molina JA, Rivero A, Pasquau J, Rubio R, Estebanez M, Sanz J, et al. Safety and efficacy of switching to dual therapy (atazanavir/ritonavirRlamivudine) vs. triple therapy (atazanavir/ritonavirRtwonucleos(t)ides) in patients on virologically stable antiretroviral therapy: 24-week interim analysis from a randomized clinical trial (SALT Study) [abstract P7/A9]. 14th EACS; 16-19 October 2013; Brussels, Belgium.
10. Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir as a single-drug therapy for maintenance of HIV-1 viral suppression. 48-week results of a randomised, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-287.
11. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Pérez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
12. Nunes EP, de Oliveira MS, Merçon M, Zajdenverg R, Faulhaber JC, Pilotto JH, et al. Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KAlMO Study). HIV Clin Trials 2009; 10:368-374.
13. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girad PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.
14. Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010; 24:223-230.
15. d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, et al. Durability of lopinavir/ritonavir mono-therapy in individuals with viral load < 50 copies/mL in the observational setting. Antivir Ther 2014; 19:319-324.
16. Paton N, Stöhr W, Arenas-Pinto A, Dunn D for the PIVOT Trial Team. Randomised controlled trial of a PI monotherapy switch strategy for long-term HIV management (The PIVOT Trial) [abstract 550LB]. Conference on Retrovirus and Opportunistic Infections; 3-6 March 2014, Boston, MA.
17. Curran A, Monteiro P, Domingo P, Villar J, Imaz A, Martinez E, et al. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: Same results as in clinical trials? The PIMOCS Study Group. J Antimicrob Chemother 2014; 69:1390-1396.
18. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitors monotherapy versus combination antiretroviral maintenance therapy: A meta-analysis. PLoS One 2011; 6:e22003.
19. European AIDS Clinical Society Guidelines [version 7.0]. October 2013. HTTP://eacssociety.org/guidelines.aspx[Accessed 11 December 2013].
20. National Consensus Document by GESIDA/National Aids Plan on Antiretroviral Treatment in Adults Infected by the Human Immunodeficiency Virus (January 2011 Update). Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin 2011; 29:209.e1-209.e103.
21. Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012; 35:113-159.
22. Cossarini F, Salpietro S, Galli L, Gianotti N, Nozza S, Spagnuolo V, et al. Monotherapy with atazanavir as a simplification strategy: results from an observational study. J Acquir Immune Defic Syndr 2012; 60:e101-e103.
23. Guiguet M, Ghosn J, Duvivier C, Meynard JL, Gras G, Partisani M, et al. Boosted protease inhibitor monotherapy as a maintenance strategy: An observational study. AIDS 2012; 26:2345- 2350.
24. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417-422.
25. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, et al. The role of compartment penetration in PI-monotherapy: The atazanavir-ritonavir mono maintenance (ATARITMO) trial. AIDS 2007; 21:13-15.
26. Wilkin TJ, McKinnon JE, Di Rienzo AG, Mollan K, Fletcher CV, Margolis DM, et al. Regimen simplification to atazanavirritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
27. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
28. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
30. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, et al. Patient-reported non adherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24:123-128.
31. Antinori A, Cozzi-Lepri A, Ammassari A, Trotta MP, Nauwelaers D, Hoetelmans R, et al. Relative prognostic value of selfreported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9:291-296.
32. National Institute of Allergy and Infectious Diseases, Division of AIDS (DAIDS), Regulatory Support Center. Table for grading the severity of adult and paediatric adverse events. Version 1, December 28, 2004; Clarification August 2009. http://rsc.techres.com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf [Accessed May 2010].
33. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top HIV Med 2011; 19:156-163.
34. Arribas J, Pulido F, Hill A, Delft YV, Moecklinghoff C. Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. Int J STD AIDS 2013; 24:679-681.
35. Santoro MN, Armenia D, Alteri C, Fiandre P, Calcagno A, Santoro M, et al. Impact of pretherapy viral load on virological response to modern first-line HAART. Antivir Ther 2013; 18:867-876.
36. Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011; 204:1211-1216.
37. Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14:195- 201.
38. Quaranta MG, Mattioli B, Vella S. Glances in immunology of HIV and HCV infection. Adv Virol 2012; 2012:434036.
39. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, et al. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis coinfected patients: results from the Icona Foundation study. BMC Infect Dis 2014; 12:14-79.
40. Geretti AM, Arribas JR, Lathouwers E, Foster GM, Yakoob R, Kinloch S, et al. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. HIV Clin Trials 2013; 14:45-50.
41. Arribas JR, Delgado R, Arranza A, Munoz R, Portilla J, Pasquau J, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-152.
42. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial:week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transriptase inihibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13:398-405.
43. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study. J Infect Dis 2013; 207:1359-1369.
44. Caron-Debarle M, Boccara F, Lagathu C, Antoine B, Cervera P, Bastard JP, et al. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Res 2010; 16:3352-3360.
45. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, et al. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS clinical trials group study A5224s. AIDS 2014. [Epub ahead of print].